The NHS is expanding access to Stereotactic Ablative Radiotherapy (SABR) for prostate cancer patients, a precision treatment capable of reducing a standard 20-dose radiotherapy course to just five sessions. This rollout, reaching 48 providers across England, coincides with increased public attention on prostate health following Jeremy Clarkson’s recent disclosure of an aggressive but early-stage diagnosis, which he treated using high-intensity focused ultrasound (HIFU).
Precision Radiotherapy: How SABR Works
SABR delivers high-intensity radiation with pinpoint accuracy, minimizing damage to healthy tissue surrounding a tumor. Simon Grieveson, assistant director of research at Prostate Cancer UK, compares the technology to multiple torches focused on a single point. “The intensity of the brightness is higher in that point where they all meet,” Grieveson explains. By concentrating beams, clinicians can effectively target cancerous cells while sparing surrounding tissue.
For patients like Edwin Lambert, 70, who was diagnosed with adenocarcinoma after his PSA levels spiked to 22.9ng/mL, the treatment offered a faster alternative to traditional surgery or long-term radiotherapy. Lambert, who joined a study in July 2025, received his radiation in five doses over 10 days. While he experienced side effects including radiation-induced cystitis and hormone-therapy-related symptoms, he noted that the treatment process itself was efficient, with individual sessions lasting only seven seconds on the latest equipment.
NHS modelling suggests that approximately one in five men eligible for SABR will choose it, reflecting a shift toward personalized, less invasive care.
Comparing Treatment Pathways
The landscape for prostate cancer care is moving away from a “one-size-fits-all” approach, according to Prostate Cancer UK. Patients and clinicians now evaluate multiple factors, including tumor localization, stage, and potential side effects, before deciding on a path forward.
| Treatment | Mechanism | Primary Benefit |
|---|---|---|
| HIFU | Sound waves heat/destroy cells | Preserves healthy prostate tissue |
| SABR | Focused radiation beams | Fewer sessions, high precision |
| Prostatectomy | Surgical removal | Removal of the entire prostate |
Future Research and Advanced Disease
While SABR is currently standard for low to intermediate-risk patients, research is ongoing to determine its efficacy for more advanced cases. Prostate Cancer UK is investing £865,000 in the STAR-TRAP study, led by The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research. The study aims to see if SABR can delay the progression of incurable prostate cancer that has spread, potentially allowing men to postpone chemotherapy.
“We’re moving into this more precision medicine approach, personalised approach, rather than one-size-fits-all,” Grieveson says. As genetic profiling and targeted therapies evolve, the goal is to identify specific treatments tailored to the biological characteristics of an individual’s cancer.
If you have concerns about prostate health, don’t wait for symptoms. Talk to your GP about a PSA blood test. Early detection remains the most effective way to ensure a wider range of treatment options, including focal therapies like HIFU or SABR.
Frequently Asked Questions
Who is eligible for SABR treatment on the NHS?
SABR is currently being rolled out for men with low to intermediate-risk prostate cancer. Eligibility is determined by clinical teams based on the stage and spread of the disease.
What are the common side effects of SABR?
Patients may experience radiation-induced cystitis, bowel disturbances, and symptoms related to hormone therapy, such as hot flushes or erectile dysfunction. Many patients report these effects are manageable and shorter in duration than those associated with traditional radiotherapy.
How does SABR differ from traditional radiotherapy?
Traditional radiotherapy often requires 20 daily doses. SABR uses highly focused beams to deliver the required treatment in significantly fewer sessions—typically five—reducing the overall time commitment for the patient.
For more information on prostate health and support, visit Prostate Cancer UK. Have you or a family member navigated a cancer diagnosis? Share your experiences in the comments below to help others feel less alone.
Keep reading